“We’ve put sales reps now in San Francisco, San Diego, Los Angeles, Austin, Houston, New York City—these are the areas that we’re seeing large investments in life science and startup life science companies,” says PTP President Ethan Simmons.
Fast-growing Amazon Web Services partner and cloud services standout Pinnacle Technology Partners (PTP) has acquired two managed service providers (MSPs) over the past several weeks to boost its life science business as PTP expands globally.
This week, Norwood, Mass.-based biotech and life science-focused PTP acquired life science MSP Stratogent, based in San Mateo, Calif., which has over 300 client-facing engineers.
“So we’ll be a 400-person company now with offices across the country and a large team of offshore resources that we’ll be using to continue to deliver more services to our customers,” PTP President Ethan Simmons told CRN. “We’ve put sales reps now in San Francisco, San Diego, Los Angeles, Austin, Houston, New York City—these are the areas that we’re seeing large investments in life science and startup life science companies.”
[Related: Google-Wiz Deal: 5 Huge Microsoft, AWS, AI And Google Cloud Things To Know]
Last month, PTP also acquired cloud and network MSP Protocol Networks, which also focuses on life science companies.
PTP plans to integrate both Wrentham, Mass.-based Protocol Networks as well as Stratogent’s services into a unified platform.
AI Is Boosting Life Science Industry
PTP is an innovative AWS and Cisco partner that provides cloud consulting and managed services tailored toward the life science and biotechnology markets. PTP made CRN’s 2025 Managed Service Provider 500 list for the Pioneer 250 category.
Simmons said artificial intelligence is playing a role in PTP’s decision to expand into new markets as demand for AI solutions is high.
“We are seeing more and more use cases for AI to accelerate drug discovery,” said Simmons. “It’s at the top of everyone’s mind, ‘How do I leverage AI to further accelerate drug discovery?”
Both AWS and Cisco have invested heavily in AI over the past several years around infrastructure, networking, cybersecurity and generative AI platforms.
Furthermore, Simmons said the life science market is constantly being fueled by venture capital funding.
“It’s a market that there’s always investment in. It does go up and down at times, but from a venture capital standpoint, there’s always money going into life sciences,” said Simmons.”
“It’s a long game that these investors are playing. It takes years and years to get a drug to market. So early-stage investments are always going on because people are always looking to try to find the next cure,” he said.
PTP’s MSP niche in the life sciences and biotech industry is on purpose.
“All the other large MSPs out there are sort of jack of all trades. They try to be everything to everyone,” Simmons said. “We decided that life sciences was an industry that we could hyper-verticalize on and be really good at understanding the applications, the workflows and the business needs that these companies have to deliver highly curated solutions just to help them do work faster, which is trying to bring cures to market faster.”
